• Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus

  In this issue: Knock on effects of the Valsartan recall, the future of AI in...
  Read More...

• New insights into epicutaneous immunotherapy for peanut allergy

  In GlobalData’s analysis of the emerging peanut allergy market titled Peanut Allergy: Opportunity Analysis and...
  Read More...

• Starting young: Aimmune begins new trial treating peanut allergy in toddlers

  On December 19 Aimmune Therapeutics announced the initiation of its Phase III POSEIDON trial exploring...
  Read More...

• Tremfya vs. Cosentyx: Will IL-23s surpass IL-17s in the psoriasis market?

  Data from the Phase III ECLIPSE head-to-head trial for Johnson & Johnson’s (J&J) interleukin 23...
  Read More...

• New Phase I data for ASN002 shows promise

  New Phase I data for ASN002 shows promise for JAK-SYK dual inhibitors in atopic dermatitis.
  Read More...

• Roche’s Tecentriq triplet versus Keytruda + chemotherapy: an Uphill Struggle?

  On December 7 Roche announced the FDA approval of its triplet of programmed death-ligand 1...
  Read More...

• Will the UK relax its current regulations for cannabis-based products?

  Recently medicinal cannabis has been at the forefront of media attention in the UK, and...
  Read More...

• Could Bristol-Myers Squibb change the psoriasis market?

  The psoriasis drug market is  fiercely competitive, and strongly held by large pharmaceutical companies that...
  Read More...

• CAR-T toxicity rating system to be finalized by ASBMT by year-end

  The American Society of Blood and Marrow Transplantation (ASBMT) is in the process of developing...
  Read More...

• Why are novel therapies for glioblastoma patients not gaining approvals?

  Despite the abundance of approvals and launches of novel therapies in the oncology space, glioblastoma...
  Read More...